| 000 | 01822 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515110053.0 | ||
| 264 | 0 | _c20080411 | |
| 008 | 200804s 0 0 eng d | ||
| 022 | _a1471-2407 | ||
| 024 | 7 |
_a10.1186/1471-2407-8-46 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDiaconu, Nicolae-Costin | |
| 245 | 0 | 0 |
_aCervical squamous carcinoma cells are resistant to the combined action of tumor necrosis factor-alpha and histamine whereas normal keratinocytes undergo cytolysis. _h[electronic resource] |
| 260 |
_bBMC cancer _cFeb 2008 |
||
| 300 |
_a46 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xdrug therapy |
| 650 | 0 | 4 |
_aCell Death _xdrug effects |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aCytotoxins _xadministration & dosage |
| 650 | 0 | 4 |
_aDNA, Neoplasm _xdrug effects |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHistamine _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKeratinocytes _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xadministration & dosage |
| 650 | 0 | 4 |
_aUterine Cervical Neoplasms _xdrug therapy |
| 700 | 1 | _aRummukainen, Jaana | |
| 700 | 1 | _aMättö, Mikko | |
| 700 | 1 | _aNaukkarinen, Anita | |
| 700 | 1 | _aHarvima, Rauno J | |
| 700 | 1 | _aPelkonen, Jukka | |
| 700 | 1 | _aHarvima, Ilkka T | |
| 773 | 0 |
_tBMC cancer _gvol. 8 _gp. 46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1471-2407-8-46 _zAvailable from publisher's website |
| 999 |
_c17763439 _d17763439 |
||